menu
    • menu
    [{"orgOrder":0,"company":"Immunomedics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Sacituzumab Govitecan","moa":"||Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunomedics \/ Immunomedics","highestDevelopmentStatusID":"7","companyTruncated":"Immunomedics \/ Immunomedics"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0.46000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.46000000000000002,"dosageForm":"Injection","sponsorNew":"Immunomedics \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Cowen"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunomedics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Undisclosed"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunomedics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Undisclosed"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunomedics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunomedics \/ Undisclosed"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunomedics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Undisclosed"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.46000000000000002,"dosageForm":"Injection","sponsorNew":"Immunomedics \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Cowen"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Dla Piper","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0.47999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.47999999999999998,"dosageForm":"Injection","sponsorNew":"Immunomedics \/ Dla Piper","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Dla Piper"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Acquisition","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":21,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":21,"dosageForm":"Injection","sponsorNew":"Immunomedics \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Gilead Sciences"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Acquisition","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":21,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":21,"dosageForm":"Injection","sponsorNew":"Immunomedics \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Gilead Sciences"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunomedics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Undisclosed"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunomedics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Undisclosed"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Acquisition","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0.46000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.46000000000000002,"dosageForm":"Injection","sponsorNew":"Immunomedics \/ Immunomedics","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Immunomedics"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunomedics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immunomedics \/ Undisclosed"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunomedics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunomedics \/ Undisclosed"},{"orgOrder":0,"company":"Immunomedics","sponsor":"ProteoNic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunomedics \/ Immunomedics","highestDevelopmentStatusID":"1","companyTruncated":"Immunomedics \/ Immunomedics"}]

    Find Clinical Drug Pipeline Developments & Deals by Immunomedics

    Menu

    Immunomedics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Everest Medicines

                            Deal Size : $455.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro For...

                            Details : Under the agreement, Everest Medicines will transfer all development and commercialization rights to Gilead for Trodelvy® (sacituzumab govitecan), a first-in-class Trop-2 directed antibody-drug conjugate, in Greater China and South Korea, among Other As...

                            Product Name : Trodelvy

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $280.0 million

                            March 26, 2023

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Everest Medicines

                            Deal Size : $455.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative ...

                            Details : In single-arm Phase 2 study, Trodelvy demonstrated an ORR of 33.3 percent and a median DoR of 7.7 months, as determined by local assessment, in 108 adult TNBC patients who had previously received a median of three prior systemic therapies in the metastat...

                            Product Name : Trodelvy

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            April 22, 2022

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Gilead Sciences

                            Deal Size : $21,000.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Gilead Sciences Completes Acquisition of Immunomedics

                            Details : Gilead gains Trodelvy, Immunomedics' lead ADC, is the first ADC the FDA has approved for the treatment of people with metastatic triple-negative breast cancer and is also the first FDA-approved anti-Trop-2 ADC.

                            Product Name : Trodelvy

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $15,000.0 million

                            October 23, 2020

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Gilead Sciences

                            Deal Size : $21,000.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : ProteoNic

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ProteoNic Announces Licensing of Technology for Production of Biologics to Immunomedics

                            Details : Under the agreement, Immunomedics gains commercial rights for application of ProteoNic’s technology platform to the development of specified proprietary products from mammalian cells.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 20, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : ProteoNic

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma

                            Details : Trodelvy has shown encouraging activity in an early-stage study in brain cancers, including partial responses in small cohorts of patients with brain metastasis from breast cancer and recurrent glioblastoma.

                            Product Name : Trodelvy

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            October 12, 2020

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Ur...

                            Details : Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC).

                            Product Name : Trodelvy

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            September 19, 2020

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immunomedic's Trodelvy™ Encouraging Early-Stage Clinical Results

                            Details : Results include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM).

                            Product Name : Trodelvy

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            September 18, 2020

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Gilead Sciences

                            Deal Size : $21,000.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Gilead Sciences to Acquire Immunomedics

                            Details : Acquisition provides Gilead with TrodelvyTM (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate that was granted accelerated approval by the FDA for the treatment of adult patients with metastatic triple-negative breast...

                            Product Name : Trodelvy

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $15,000.0 million

                            September 13, 2020

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Gilead Sciences

                            Deal Size : $21,000.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Govitecan,Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Immunomedics Expands Collaboration with Roche Evaluating TrodelvyTM

                            Details : Collaboration aims to evaluate Trodelvy in combination with Tecentriq in patients with metastatic urothelial cancer and metastatic non-small cell lung cancer. Roche will be conducting two open-label, randomized Phase 1b/2 studies using its MORPHEUS platf...

                            Product Name : Trodelvy

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            July 13, 2020

                            Lead Product(s) : Sacituzumab Govitecan,Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Immunomedics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVYTM

                            Details : Trodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in previously-treated brain metastasis negative patients with advanced mTNBC.

                            Product Name : Trodelvy

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            July 06, 2020

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth